Even though it is known that p53 is an independent predictor of poor survival and poor response to neoadjuvant chemotherapy in MPNSTs [28, 31], how p53 function influences MPNST therapeutic response is not fully understood. This evidence concerns the gene TP53 and malignant peripheral nerve sheath tumor.